Regulatory Filings • Apr 9, 2015
Regulatory Filings
Open in ViewerOpens in native device viewer
PRESS RELEASE
April 8, 2015 – New York (USA) – Cellectis (Nasdaq: CLLS) a pioneering gene-editing company employing proprietary technologies to develop best-in-class products in the emerging field of immuno-oncology using Chimeric Antigen Receptor T-cell therapies (CAR-T) for the treatment of cancer, announced today it has established a new subsidiary, Cellectis, Inc. in New York City at the Alexandria Center for Life Science, located on Manhattan's east side. The U.S. headquarters' 12,000 square feet includes large state-of-the-art research laboratories. These labs will support the development of its CAR-T pipeline, a significant part of its innovation in oncology research, as well as other types of therapeutic indications.
"We were convinced by the outstanding potential of New York City, one of the fastest expanding biotech hubs in the world. At the Alexandria Center for Life Science, Cellectis is surrounded by renowned academic and medical institutions, leaders from the commercial life sciences industry, and the world's most robust financial markets," said Dr. André Choulika, Founder, Chief Executive Officer and Chairman of Cellectis.
"Cellectis choosing to establish their U.S. headquarters and research center in New York City and at the Alexandria Center for Life Science is another positive indicator for the growth of the cluster, and their cutting-edge research in immuno-oncology using CAR-T cells will be enhanced through the opportunity to collaborate with the world-class academic and medical institutions, along with other leading biotech and pharma companies here in New York," said John Cunningham, Senior Vice President and Regional Market Director, Alexandria Real Estate Equities, Inc.
Cellectis utilizes gene editing to produce CAR-T cells with unique qualities and features, including, for the first time, to be allogeneic, or "off-the-shelf." CAR-Ts that are off-the-shelf can be produced more efficiently, and can be shipped to patients worldwide. Gene editing converts a therapeutic service brought to patient into "Smart Drugs".
Cellectis Inc. is hosting a Grand Opening reception at the new facilities in Manhattan NY on April 16. To find out more about that event, click here: www.cellectis.com/sites/OpeningNYC.jpeg
Jennifer Moore, Director of Communications Phone: +1 917-580-1088 e-mail: [email protected]
Simon Harnest, VP Finance and Investor Relations Phone: +1 646-385-9008 email: [email protected]
BMC Communications - New York City Brad Miles Phone: 646-513-3125 e-mail: [email protected]
Cellectis is a gene-editing company focused on developing immunotherapies based on gene edited engineered CAR-T cells (UCART). The company's mission is to develop a new generation of cancer therapies based on engineered T-cells. Cellectis capitalizes on its 15 years of expertise in genome engineering - based on its flagship TALEN™ products and meganucleases and pioneering electroporation PulseAgile technology - to create a new generation of immunotherapies. CAR technologies are designed to target surface antigens expressed on cells. Using its lifescience-focused, pioneering genome-engineering technologies, Cellectis' goal is to create innovative products in multiple fields and with various target markets. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.cellectis.com
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.
